Roivant Sciences Ltd. (ROIV) Stock: Price, Forecast & Analyst Target
Roivant Sciences Ltd. (ROIV) — MoonshotScore 27/100 (Weak band), calculated Nov 18, 2026. Price $38.96 (+0.59%), as of the Nov 19, 2026 trading session; market cap $28.2B.
Educational signal · not a buy or sell recommendation · How to read this
Roivant Sciences Ltd. · ROIV · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: Roivant Sciences is a drug developer spanning oncology, hematology, immunology, dermatology, rare disease and infectious disease, not a mature biotechnology company whose reported revenue tracks medicine demand. Its case rests on whether that broad pipeline can create valuable therapies before sustained research spending consumes too much of its financial cushion.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Roivant Sciences (ROIV)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet and durable growth, but weak quality and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Sound; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $2M (Q2 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 44.15 · Piotroski F 2
Holding back: weak fundamentals
Helping: balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 31 | Weak | |
| 31 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 27 | Weak | |
| 27 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $38.96 | |
| Change on the day | +0.59% | |
| 52-week range | $19.96–$42.50 | |
| Market capitalisation | $28.2B | — |
| Price / earnings (trailing) | -21.81 | |
| Shares traded on the day | 4.93M | |
| Beta (volatility vs the S&P 500) | 1.2 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Roivant Sciences (ROIV): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Roivant Sciences (ROIV), and what does it report?
Short answer · as of
Roivant discovers and advances therapeutic candidates across a wide disease range.
Research dated 2026-09-12.
The income statement currently measures a development organization: revenue is reported through a consolidated segment and remains minor beside research and administrative expense, so sales trends reveal little about the pipeline’s economic potential.
Reported net income can also diverge sharply from operating performance. Profitable periods have appeared despite deep operating losses, making research expense, operating loss and cash use more informative measures of the underlying business than headline earnings alone.
What do the latest results show for Roivant Sciences (ROIV)?
Short answer · as of
The most recent reported quarter, Q2 FY2025, carried revenue of $2M.
Research dated 2026-09-12.
The latest period showed lower revenue, higher research spending, a wider operating loss and heavier operating cash use. Net income also swung back to a loss after the preceding period’s profit, while revenue again fell short of the prevailing estimate.
The mechanism is straightforward: Roivant is funding drug development at a scale far beyond its current revenue base. Rising research expense therefore widens the operating deficit unless program economics, licensing income or eventual medicine sales begin contributing enough to absorb that spending.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2025 | $2M | -$114M | -$0.17 (diluted) |
| Q3 FY2025 | $2M | -$266M | -$0.38 (diluted) |
| Q4 FY2025 | $3M | $303M | $0.37 (diluted) |
| Q1 FY2026 | $1M | -$190M | -$0.26 (diluted) |
What are the financial strengths and risks for Roivant Sciences (ROIV)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash and investments substantially exceed debt and liabilities, giving Roivant meaningful capacity to keep funding development. Liquidity ratios and low financial leverage reinforce that strength, but operating cash flow has remained negative throughout the reported series and the cash balance has declined materially.
That cushion does not remove pipeline risk. A clinical setback, delay or abandoned program can destroy expected value while research and administrative costs continue, and the market value already stands far above net cash; the valuation therefore depends chiefly on therapeutic outcomes rather than balance-sheet assets.
Data-derived red flags
- Negative return on equity (-8.5%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Roivant Sciences (ROIV)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $157.85M · EPS -1.15 · 7 analysts.
Research dated 2026-09-12.
Research spending, operating loss and operating cash use should be read together. Stabilizing cash consumption while programs advance would preserve strategic room; another acceleration in burn without a corresponding improvement in pipeline economics would make the cash reserve less protective.
Reported revenue should be judged against its limited role rather than treated as a conventional sales-growth signal. The useful near-term checks are whether revenue continues missing expectations, whether the loss profile worsens, and whether the cash balance keeps falling at the recent pace.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q2 FY2025) was filed Nov 10, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Roivant Sciences compare with its peers?
Short answer
Roivant Sciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Compared with a biotechnology company built around an established commercial franchise, Roivant offers broader therapeutic exposure but far less support from current product economics. Its defining combination is a wide development pipeline, negligible reported revenue, heavy research spending and unusually strong liquidity relative to debt.
Compared with a narrowly financed development-stage peer, Roivant can sustain more setbacks before financing pressure dominates. The tradeoff is that its market value exceeds its net cash by a wide margin, while long-range revenue estimates span a broad range; investors are paying mainly for uncertain pipeline value rather than present earnings power.
| Company | Price | Market value | Score |
|---|---|---|---|
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $255.96 Nov 19, 2026 | $16.8B | 96 5-pillar Nov 18, 2026 | |
| $942.04 Nov 19, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $72.70 Nov 19, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $64.88 Nov 19, 2026 | $9.81B | 90 5-pillar Nov 18, 2026 | |
| $68.67 Nov 18, 2026 | $39.5B | 73 5-pillar Nov 18, 2026 | |
| $50.97 Nov 18, 2026 | $31.4B | 72 5-pillar Nov 18, 2026 | |
| $149.40 Nov 18, 2026 | $20.0B | 72 5-pillar Nov 18, 2026 | |
| Roivant Sciences (ROIV) — this page | $38.96 | $28.2B | 27 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $41.00 – $62.00
- Consensus target
- $49.50
- Median target
- $49.00
- Revenue estimate
- $157.85M
- EPS estimate
- $-1.15
Consensus record · Captured .
Measured against a quoted price of $38.96 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 100
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 26
- Other transactions
- 74
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ROIV in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.76% | $247.12M | Added +7.7% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Roivant Sciences (ROIV)?
Common Questions About ROIV (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why does Roivant’s oncology-to-immunology pipeline produce so little reported revenue?
Roivant is primarily advancing therapeutic candidates rather than harvesting a mature commercial portfolio. Its reported revenue is therefore small beside research spending and does not capture the potential value of programs still under development.
Why can Roivant’s net result turn positive while its operating result remains deeply negative?
The divergence indicates that items outside core operations can dominate the headline result. Persistent operating losses show that the development organization itself remains costly regardless of occasional reported profits.
Can Roivant’s thin reported revenue fund its broad drug-development program?
Current revenue covers only a small portion of research and administrative spending, leaving cash reserves to finance the gap. Continued negative operating cash flow confirms that the program is not self-funding.
What would make Roivant’s large cash reserve less reassuring as research spending rises?
Persistent cash consumption without stronger program economics would steadily reduce the protection that liquidity provides. The warning pattern would be rising research expense, widening operating losses and continued erosion of cash and short-term investments.
What is the ROIV stock price today?
The last price recorded for Roivant Sciences Ltd. (ROIV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ROIV price target?
The analyst consensus price target for Roivant Sciences Ltd. (ROIV), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 28 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold ROIV
Funds in our ETF coverage that list ROIV among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| State Street SPDR S&P Biotech ETF (XBI) | 1.74% |